엠투엔

033310KOSDAQ

71.5 / 100

Reference Date: 2026-09-08

Financial Score22.5 / 40

News Sentiment20.0 / 25

Momentum14.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 8.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

M2N operates three business segments: steel drum manufacturing, automotive HVAC components, and biopharmaceutical development. The steel drum business produces and sells steel drums for petrochemical packaging, while the automotive segment supplies HVAC parts to vehicle manufacturers and exports to Southeast Asia. The biopharma division is developing new drugs through U.S. subsidiaries, targeting FDA approval and future revenue via license-out deals. Steel drums and automotive components account for 39.9% and 58.8% of total sales, respectively.

Number of Employees

208people

Average Salary

53.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.40Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-0.41Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

13.09Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲6.7% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼4.7% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.4% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
신라젠 ‘BAL0891’ FDA 희귀의약품 지정…고형암 넘어 혈액암까지
신라젠의 주요 항암 후보물질 BAL0891이 FDA로부터 희귀의약품 지정을 받으며, 이는 엠투엔에 대한 긍정적 투자 신호를 제공하고 추가 연구 자금 확보 및 시장 독점권 강화로 이어져 긍정적 영향을 미칠 것으로 예상된다.
Positive
엠투엔, 2Q 매출액 448억원에 영업이익 14억원…"재무구조 안정화"
엠투엔의 상반기 실적 개선으로 재무구조 안정화 기대

Detailed Momentum

52-week position3.0Point

52w lower range (22%)

Current 1,450Won52-week high 2,28052-week low 1,206

1-month return5.0Point

1m +8.45% (rising)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

7 totalPositive 3Neutral 4Negative 0

Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-09-07
Neutral주식등의대량보유상황보고서(일반)2026-08-25
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-08-18
Neutral주식등의대량보유상황보고서(일반)2026-08-14
Neutral반기보고서 (2026.06)2026-08-14